Back to Search
Start Over
Abstract GS3-04: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)
- Publication Year :
- 2018
-
Abstract
- Supplement: S, Meeting Abstract: GS3-04.Wos title: A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)
Details
- Database :
- OAIster
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1235181668
- Document Type :
- Electronic Resource
- Full Text :
- https://doi.org/10.1158.1538-7445.SABCS17-GS3-04